These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27043753)

  • 1. Guiding Oncology Patients Through the Maze of Precision Medicine.
    Giuse NB; Kusnoor SV; Koonce TY; Naylor HM; Chen SC; Blasingame MN; Anderson IA; Micheel CM; Levy MA; Ye F; Lovly CM
    J Health Commun; 2016; 21 Suppl 1(Suppl):5-17. PubMed ID: 27043753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information.
    Kusnoor SV; Koonce TY; Levy MA; Lovly CM; Naylor HM; Anderson IA; Micheel CM; Chen SC; Ye F; Giuse NB
    AMIA Jt Summits Transl Sci Proc; 2016; 2016():112-21. PubMed ID: 27570660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of health literacy interventions on the informed consent process of health care users: a systematic review protocol.
    Perrenoud B; Velonaki VS; Bodenmann P; Ramelet AS
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):82-94. PubMed ID: 26571285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward rapid learning in cancer treatment selection: An analytical engine for practice-based clinical data.
    Finlayson SG; Levy M; Reddy S; Rubin DL
    J Biomed Inform; 2016 Apr; 60():104-13. PubMed ID: 26836975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using health literacy and learning style preferences to optimize the delivery of health information.
    Giuse NB; Koonce TY; Storrow AB; Kusnoor SV; Ye F
    J Health Commun; 2012; 17 Suppl 3():122-40. PubMed ID: 23030566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
    Atkins MB
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.
    Cheng L; Lopez-Beltran A; Massari F; MacLennan GT; Montironi R
    Mod Pathol; 2018 Jan; 31(1):24-38. PubMed ID: 29148538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.
    Løes IM; Immervoll H; Angelsen JH; Horn A; Geisler J; Busch C; Lønning PE; Knappskog S
    Tumour Biol; 2015 Feb; 36(2):1003-13. PubMed ID: 25318602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized oncology and BRAF
    Keller BA; Laight BJ; Varette O; Broom A; Wedge MÈ; McSweeney B; Cemeus C; Petryk J; Lo B; Burns B; Nessim C; Ong M; Chica RA; Atkins HL; Diallo JS; Ilkow CS; Bell JC
    J Cancer Res Clin Oncol; 2021 May; 147(5):1365-1378. PubMed ID: 33555379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.
    Wilmott JS; Tembe V; Howle JR; Sharma R; Thompson JF; Rizos H; Lo RS; Kefford RF; Scolyer RA; Long GV
    Mol Cancer Ther; 2012 Dec; 11(12):2704-8. PubMed ID: 22962325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
    McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
    Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
    Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annotation-Free Deep Learning-Based Prediction of Thyroid Molecular Cancer Biomarker BRAF (V600E) from Cytological Slides.
    Wang CW; Muzakky H; Lee YC; Lin YJ; Chao TK
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine.
    Mounajjed T; Brown CL; Stern TK; Bjorheim AM; Bridgeman AJ; Rumilla KM; McWilliams RR; Flotte TJ
    Hum Pathol; 2014 Nov; 45(11):2240-6. PubMed ID: 25179409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.